New registry to monitor growth hormone treatment in kids with rare genetic condition
NCT ID NCT05308927
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 19 times
Summary
This study is a registry that will follow up to 221 children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. Researchers will track how their height changes over time, any side effects, and their quality of life. The goal is to gather real-world information on the long-term effects and safety of this growth hormone treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOONAN SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ap-Hp-Hopital de Bicetre-2
Le Kremlin-Bicêtre, 94275, France
-
Centre Hospitalier Universitaire D'Angers-2
Angers, 49033, France
-
Hopital Des Enfants-2
Toulouse, 31059, France
Conditions
Explore the condition pages connected to this study.